What is chemotherapy-induced nausea and vomiting?

Chemotherapy is a type of cancer treatment. The goal of chemotherapy is to kill harmful cancer cells. Chemotherapy affects both cancer cells and normal cells.

Nausea and vomiting can be a side effect of chemotherapy. Nausea can lead to vomiting, which is throwing up the contents of your stomach. Nausea and vomiting due to your chemotherapy treatment is called chemotherapy-induced nausea and vomiting, or CINV.

  • Nausea is the feeling you have when you are going to throw up

  • Vomiting (emesis) is the act of throwing up what is in your stomach

Some chemotherapy treatments may cause nausea and vomiting that can last for up to 5 days.

Will my chemotherapy cause nausea and vomiting?

Not all chemotherapy causes nausea and vomiting. Nausea and vomiting can start right after you receive chemotherapy or sometimes days later. You may not get nauseated or vomit during treatment. You may experience nausea or vomiting, or both. Your healthcare team can tell you if your chemotherapy is likely to cause nausea and vomiting.

How "emetic" a medicine is refers to how likely it is to cause vomiting.

  • Chemotherapy that is highly emetic means that there is a high risk it will cause nausea and vomiting

  • Chemotherapy that is moderately emetic means that there is a moderate risk it will cause nausea and vomiting

Talk to your healthcare team about how to help prevent nausea and vomiting due to chemotherapy

Important Safety Information

  • ALOXI® can cause allergic reactions that can be serious. Tell your doctor or nurse right away if you have any of these following symptoms of a serious allergic reaction: hives, swelling of the face, trouble breathing and chest pain

  • The most common side effects of ALOXI in adults are headache and constipation

  • Tell your doctor or nurse if you are taking other medications or if you are pregnant or breastfeeding or plan to become pregnant or breastfeed

Indication in Adults

ALOXI injection 0.25 mg/5 mL is used in adults to help prevent nausea and vomiting on the day of chemotherapy that is highly likely to cause nausea and vomiting, and up to 5 days following chemotherapy that is moderately likely to cause nausea and vomiting.

Indication in Pediatrics

ALOXI injection 20 mcg/kg (max 1.5 mg) is used in children 1 month old to less than 17 years of age to help prevent nausea and vomiting on the day of chemotherapy that is moderately or highly likely to cause nausea and vomiting.

For more information about ALOXI, talk to your doctor or see Full Prescribing Information.

ALOXI is available by prescription only.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.

This site is intended for residents of the United States only. Any products discussed herein may have different product labeling in different countries.

This website contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other healthcare professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent healthcare decisions, you should always consult with a physician or other healthcare provider for you, or your loved ones’, personal medical needs. All quotes included in this website represent the individual experience of some doctors, some patients, and their caregivers. Individual responses to treatment may vary. Actual identities have been changed to protect individual privacy.

To report suspected adverse reactions, contact Eisai at 1-888-422-4743 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.
Distributed by Eisai Inc. under license of Helsinn Healthcare SA, Switzerland. Marketed by Eisai Inc. and Helsinn Therapeutics (U.S.), Inc.
© 2017 Eisai Inc. All rights reserved. ALOX-US0270 03/17

Important Safety Information Expand

Important Safety Information

  • ALOXI® can cause allergic reactions that can be serious. Tell your doctor or nurse right away if you have any of these following symptoms of a serious allergic reaction: hives, swelling of the face, trouble breathing and chest pain

  • The most common side effects of ALOXI in adults are headache and constipation

  • Tell your doctor or nurse if you are taking other medications or if you are pregnant or breastfeeding or plan to become pregnant or breastfeed

Indication in Adults

ALOXI injection 0.25 mg/5 mL is used in adults to help prevent nausea and vomiting on the day of chemotherapy that is highly likely to cause nausea and vomiting, and up to 5 days following chemotherapy that is moderately likely to cause nausea and vomiting.

Indication in Pediatrics

ALOXI injection 20 mcg/kg (max 1.5 mg) is used in children 1 month old to less than 17 years of age to help prevent nausea and vomiting on the day of chemotherapy that is moderately or highly likely to cause nausea and vomiting.

For more information about ALOXI, talk to your doctor or see Full Prescribing Information.

ALOXI is available by prescription only.

YOU ARE NOW LEAVING ALOXI.COM

Eisai Inc. does not review the information contained on the following website for content, accuracy, or completeness. Use of and access to the information is subject to the terms, limitations, and conditions set by the website producer. Eisai Inc. makes no claims about the accuracy or any other aspect of the information contained on this website, nor does Eisai Inc. endorse this website.

CONTINUE CANCEL

Healthcare professionals

This information is intended for US healthcare professionals. Click the "CONTINUE" button below to verify that you are a US healthcare professional, or the "CANCEL" button to return to the previous page.

CONTINUE CANCEL